Watch on-demand: Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare? Wed, 04th May 2022 Article tags Covid-19 testingIn-vitro diagnosticsNext Generation Sequencing (NGS)UncategorisedGlobalIVD GatewayNext Generation Sequencing (NGS) Sequencing-based diagnostic testing has been on the uptrend, with the adoption of next-generation sequencing (NGS) testing in oncology, genetics and prenatal screening – areas where the vast majority is done – continuing to grow strongly. Now, sequencing looks set to become even more integral in the healthcare system with the Covid-19 pandemic highlighting the power of sequencing-based diagnostic testing in global efforts to combat the spread of the infectious disease; and its importance in supporting recovery efforts. In the evolving market for diagnostics, how and where can sequencing companies and other IVD players find growth opportunities. Date of recording: Wednesday, 23 September 2020Duration: 1 hour with live Q&A Presenters Chee Hew Director, data analytics & consulting, Clearstate Kathrin FrankeManaging director, Clearstate Watch the recording and gain answers to the questions: How has Covid-19 impacted EIU Healthcare’s forecast data on the global NGS market (with focus in Asia-Pacific and Europe markets) – for sequencing instruments and in test areas such as oncology, NIPT and infectious diseases? When can growth recovery be expected?What is the longer term outlook on sequencing-based testing opportunities in these areas?How is increasing competition posed by rising domestic players in countries such as China and new commercial models shaping the market?How will the market for NGS testing evolve as technology development is expected to reduce the operational cost of NGS testing for smaller volume labs?How will the growing adoption of NGS impact the use of other competing diagnostic technologies in areas such as molecular diagnostics and tissue diagnostics? Register to watch the on-demand recording Clearstate newsletterSign up to Clearstate's newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts. Sign up Wed, 04th May 2022 Article tags Covid-19 testingIn-vitro diagnosticsNext Generation Sequencing (NGS)UncategorisedGlobalIVD GatewayNext Generation Sequencing (NGS)
Clearstate newsletterSign up to Clearstate's newsletter for insights into key market data, trends and developments across IVD and Surgical segments from our specialists and analysts. Sign up